⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2335166 | 0.90 | ALDH1A1 (0.38) | — | |
| SCHEMBL7856962 | 0.90 | — | — | |
| SCHEMBL22922880 | 0.89 | ADORA1 (0.31) | — | |
| SCHEMBL22922902 | 0.89 | ADORA1 (0.31) | — | |
| SCHEMBL7852075 | 0.88 | ALDH1A1 (0.41) | — | |
| SCHEMBL7853880 | 0.88 | ALDH1A1 (0.41) | — | |
| SCHEMBL689874 | 0.86 | SLC18A3 (0.34) | — | |
| SCHEMBL1101826 | 0.82 | NPC1 (0.38) | — | |
| SCHEMBL22580260 | 0.82 | — | — | |
| SCHEMBL1414276 | 0.81 | ESR2 (0.41) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 142 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219954-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC | 2023-07-13 | — | — | US | claimed |
| US-11685736-B2 | P2X3 and/or P2X2/3 compounds and methods | ABS DEVELOPMENT 1, INC. (US) | 2023-06-27 | — | — | US | claimed |
| EP-3083619-B1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES LLC (US) | 2021-11-03 | — | — | EP | claimed |
| US-20200109143-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ABS DEVELOPMENT 1, INC. | 2020-04-09 | — | — | US | claimed |
| US-10590127-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2020-03-17 | — | — | US | claimed |
| US-10544145-B2 | P2X3 and/or P2X2/3 compounds and methods | ASANA BIOSCIENCES, LLC (US) | 2020-01-28 | — | — | US | claimed |
| US-20190248789-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ABS DEVELOPMENT 1, INC. | 2019-08-15 | — | — | US | claimed |
| US-20180186793-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ABS DEVELOPMENT 1, INC. | 2018-07-05 | — | — | US | claimed |
| US-20180141945-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ABS DEVELOPMENT 1, INC. | 2018-05-24 | — | — | US | claimed |
| EP-2991987-B1 | PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | HOFFMANN LA ROCHE (CH) | 2018-05-23 | — | — | EP | claimed |
| US-20150376192-A1 | NOVEL PYRAZOL DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2015-12-31 | — | — | US | claimed |
| EP-2776442-B1 | [1, 2, 3]TRIAZOLO [4, 5 -D]PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 | HOFFMANN LA ROCHE (CH) | 2015-10-21 | — | — | EP | claimed |
| WO-2015095128-A1 | P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS | ASANA BIOSCIENCES, LLC (US) | 2015-06-25 | — | — | WO | claimed |
| WO-2014177490-A1 | PURINE DERIVATIVES AS CB2 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-11-06 | — | — | WO | claimed |
| EP-2776442-A1 | [1, 2, 3]TRIAZOLO [4, 5 -D]PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 | F.HOFFMANN-LA ROCHE AG (CH) | 2014-09-17 | — | — | EP | claimed |
| WO-2014135507-A1 | NOVEL PYRAZOL DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | claimed |
| US-8741906-B2 | [1,2,3]triazolo[4,5-D]pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2014-06-03 | — | — | US | claimed |
| CN-103328449-A | Novel tetrahydroquinoline derivatives | HOFFMANN LA ROCHE | 2013-09-25 | — | — | CN | claimed |
| WO-2013068306-A1 | [1, 2, 3] TRIAZOLO [4, 5 -D] PYRIMIDINE DERIVATIVES AS AGONISTS OF THE CANNABINOID RECEPTOR 2 | F. HOFFMANN-LA ROCHE AG (CH) | 2013-05-16 | — | — | WO | claimed |
| US-20130116236-A1 | NOVEL [1,2,3]TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2013-05-09 | — | — | US | claimed |